Bei Jing Shang Bao
Search documents
复星医药芦沃美替尼片新增适应症上市申请获受理
Bei Jing Shang Bao· 2026-02-05 10:18
北京商报讯(记者王寅浩宋雨盈)2月5日,复星医药(600196)发布公告称,公司控股子公司上海复星医 药产业发展有限公司自主研发的复迈宁(通用名:芦沃美替尼片)用于治疗伴有症状、无法手术的丛状神 经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请获国家药品监督管理局受理并已获纳入优先审评 程序。 根据公告,芦沃美替尼片为MEK1/2选择性抑制剂。目前,该药品已于中国境内(不含港、澳、台地区) 上市并获批两项适应症,包括用于治疗朗格汉斯细胞组织细胞增生症和组织细胞肿瘤成人患者以及2岁 及2岁以上伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病儿童及青少年患者。 ...
恒瑞医药SHR-1894注射液临床试验获批
Bei Jing Shang Bao· 2026-02-05 10:18
Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, a self-developed biological product aimed at treating atopic dermatitis [1] Group 1 - SHR-1894 injection is expected to protect the skin barrier and suppress inflammation during the treatment of atopic dermatitis [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1]
恒瑞医药HR091506片上市许可申请获受理
Bei Jing Shang Bao· 2026-02-05 10:18
Core Viewpoint - Heng Rui Medicine has received acceptance for its HR091506 tablet application from the National Medical Products Administration, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1 - The HR091506 tablet is developed using gastric retention formulation technology and features a pulsatile release characteristic [1] - The product consists of a rapid-release part and a delayed-release part, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] - The goal of HR091506 is to improve the rate of achieving target uric acid levels in patients [1]
叮咚买菜创始人梁昌霖回应被美团收购:叮咚的核心竞争力不会因为合并而消失
Bei Jing Shang Bao· 2026-02-05 10:18
北京商报讯(记者 何倩)2月5日,针对美团发布的收购公告,叮咚买菜创始人梁昌霖发布内部信。他表示,双方合并之后,叮咚的三大核心竞争力:极 致的商品力、超预期的服务力、和通过供应链系统打造的极致效率,不会因为合并而消失,反而会在更大的平台上发挥更大的价值。 2月5日,美团于香港联交所发布公告,将以约7.17亿美元的初始对价,完成对叮咚买菜中国业务100%股权的收购。 "我们可以一起去服务更广阔的市场,让美好的食材像自来水一样触手可及,普惠万众。"梁昌霖认为,这与美团的使命"帮大家吃得更好,生活更好"高度 契合。面向未来,公司做出了一个更具远见的决定:放下相向的较量,转为并肩的同航。这是两条强劲河流的汇合,必将奔向更加壮阔的海洋。 "当然,我们也深知河道曲折,这需要大家的共同努力。"梁昌霖说。 同时,梁昌霖提及,叮咚买菜的业务和团队会保持稳定,员工仍会有非常稳定的发展平台。而且,美团的业务版图非常广阔,这次合并为大家打开了更大 的职业空间。 可 删除 ○ 拒收 ◇ 回复 《 回复全部 c》转发 ○转发到聊天 致叮咚买菜全体同事的一封信 * 各位叮咚的同学们: 6 0 0 @ … 2/5 周四 详情 今天,我们正式 ...
春光集团创业板IPO过会
Bei Jing Shang Bao· 2026-02-05 10:18
在上市委会议现场,上市委要求春光集团结合软磁材料的市场竞争格局、下游市场需求变化、原材料价 格及毛利率变动趋势、对高性能软磁材料的技术储备以及募投项目扩产情况等,说明公司产品技术能否 适应行业技术发展趋势,公司业绩增长是否具有可持续性。 据了解,春光集团创业板IPO于2025年6月17日获得受理,当年7月1日进入问询阶段。招股书显示,春 光集团主营业务为软磁铁氧体磁粉的研发、生产和销售,并沿产业链发展软磁铁氧体磁心、电子元器件 和电源等产品。此次冲击上市,公司拟募资7.51亿元。 北京商报讯(记者 马换换 李佳雪)2月5日晚间,深交所官网显示,山东春光科技集团股份有限公司 (以下简称"春光集团")创业板IPO当日上会获得通过。 ...
任职资格已获批!吴克照出任上海华瑞银行董事长
Bei Jing Shang Bao· 2026-02-05 10:18
公开资料显示,吴克照,男,1976年生,中共党员,本科学历,正高级会计师、注册会计师。现任上海 华瑞银行股份有限公司董事长。曾任中国联通温州分公司计财部副经理、浙江分公司财务部副总经理、 萧山分公司总经理,温州银行总行计划财务部总经理,温州银行上海分行党委书记、行长,上海华瑞银 行执行董事、行长兼首席合规官。 北京商报讯(记者 宋亦桐)2月5日,北京商报记者注意到,上海华瑞银行2月4日发布公告表示,该行 于近日收到国家金融监督管理总局上海监管局出具的"沪金复[2026]46号"批复,核准吴克照该行董事长 任职资格。吴克照已就任上海华瑞银行董事长。 ...
2月6日起停牌!天汽模拟购东实股份股权,标的曾IPO未果
Bei Jing Shang Bao· 2026-02-05 10:18
北京商报讯(记者 马换换 李佳雪)2月5日晚间,天汽模(002510)披露公告称,公司正在筹划通过发 行股份及支付现金的方式购买东实汽车科技集团股份有限公司(以下简称"东实股份")股权并募集配套 资金。公司股票自2月6日起开始停牌。 值得一提的是,东实股份曾有过一段冲击IPO未果的经历。深交所官网显示,公司主板IPO于2023年5月 25日获得受理,并于当年6月25日进入问询阶段,不过,公司IPO于2024年5月17日撤单,冲A折戟。 公告显示,本次交易预计构成重大资产重组,构成关联交易,不构成重组上市。公司预计在不超过10个 交易日内披露本次交易方案,即在3月2日前按照要求披露相关信息,并申请复牌。 据悉,东实股份是一家从事汽车零部件研发、制造与销售的大型集团公司。 ...
近半数装修建材股下跌 东宏股份股价下跌2%
Bei Jing Shang Bao· 2026-02-05 10:18
Group 1 - The renovation and building materials sector experienced a slight decline, closing at 18,314.37 points with a drop of 0.03% [1] - Donghong Co. led the decline among renovation and building materials stocks, closing at 13.71 yuan per share with a decrease of 2% [1] - Aiyang Ceiling closed at 78.90 yuan per share, down 1.88%, ranking second in the decline among renovation and building materials stocks [1] Group 2 - Pinao saw an increase of 5.53%, closing at 32.8 yuan per share, leading the gains in the renovation and building materials sector [1] - Keshun Co. closed at 7.82 yuan per share, up 3.58%, ranking second in the gains among renovation and building materials stocks [1] - Gu Di Technology closed at 3.43 yuan per share, with an increase of 2.39%, ranking third in the gains among renovation and building materials stocks [1] Group 3 - China Galaxy's research report indicates that in the medium to long term, the demand for consumer building materials will be supported by the renovation of existing homes, old renovations, and urban renewal [1] - Leading companies in the consumer building materials sector are accelerating adjustments to their sales strategies, with retail business scale continuously expanding [1] - As urban development shifts towards improving existing stock, the market share of leading companies is expected to continue increasing [1]
中科曙光3套scaleX万卡超集群同步落地-独家
Bei Jing Shang Bao· 2026-02-05 10:08
北京商报讯2月5日,中科曙光宣布,由公司提供的3套万卡超集群系统在国家超算互联网郑州核心节点 同时上线试运行,成为全国首个实现3万卡部署、且实际投入运营的最大国产AI算力池,全面覆盖万亿 参数模型训练、高通量推理、AI for Science等大规模AI计算场景。 (相关资料图) ...
三棵树为三家全资子公司提供连带责任担保
Bei Jing Shang Bao· 2026-02-05 10:05
Core Viewpoint - Sanke Tree Co., Ltd. has announced the provision of guarantees for its subsidiaries to meet their operational funding needs, indicating stable business conditions and manageable risks associated with the guarantees [1] Group 1: Guarantee Contracts - The company signed a maximum principal guarantee contract with China Construction Bank's Boye Branch, providing a joint liability guarantee of RMB 200 million for Hebei Sanke Tree [1] - A maximum principal guarantee contract was also signed with Industrial and Commercial Bank of China, providing a joint liability guarantee of RMB 80 million for Anhui Sanke Tree [1] - The company plans to sign a maximum principal guarantee contract with China Construction Bank's Licheng Branch, providing a joint liability guarantee of RMB 48 million for Sanke Tree Materials [1] Group 2: Subsidiary Status - Hebei Sanke Tree, Anhui Sanke Tree, and Sanke Tree Materials are wholly-owned subsidiaries of the company, and their operational conditions are stable with good credit status [1] - The guarantees provided will not harm the interests of the company and all shareholders, nor will they adversely affect the company's normal operations and business development [1]